This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Low Price-to-Book Value Stocks That You Can Buy in June
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. USNA, CVS, PFE, STNE and PSFE are some such stocks.
PFE or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PFE vs. LLY: Which Stock Is the Better Value Option?
EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy
by Zacks Equity Research
GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for review by the EMA.
4 Value Stocks to Shield Your Portfolio Amid Geopolitical Turmoil
by Sumit Singh
As geopolitical risks jolt markets, STNE, CNC, CVS and PFE shine with low cash flow valuations and solid earnings outlooks.
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
by Kinjel Shah
In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.
Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?
by Kinjel Shah
JNJ's Innovative Medicines unit shows a growth trend, defying Stelara LOE and the negative impact of the Part D redesign.
Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds
by Kinjel Shah
PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and market headwinds.
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
by Zacks Equity Research
NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
by Zacks Equity Research
MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.
Top Cancer Stocks to Supercharge Your 2025 Portfolio
by Kinjel Shah
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip?
by Kinjel Shah
PFE lags the market as COVID sales drop and patent losses loom, but new drugs and cost cuts may fuel a comeback.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?
by Ekta Bagri
BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure
Zacks.com featured highlights JAKKS Pacific, Green Dot, Signet Jewelers, Gibraltar Industries and Pfizer
by Zacks Equity Research
JAKK, GDOT, SIG, ROCK, and PFE offer low P/S ratios and high growth potential, making them standout value plays now.
5 Bargain Stocks With Low P/S Ratios & High Growth Return Potential
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like JAKK, GDOT, SIG, ROCK and PFE hold promise.
Zacks.com featured highlights StoneCo, Centene, CVS Health and Pfizer
by Zacks Equity Research
StoneCo, Centene, CVS, and Pfizer stand out as top value picks with strong cash flow amid market uncertainty.
Moderna Secures FDA Nod for Next-Gen COVID-19 Vaccine mNexspike
by Zacks Equity Research
MRNA wins FDA approval for mNexspike, a fridge-stable COVID shot, but with a narrower use label than it sought.
Bristol Myers Collaborates With BNTX for Oncology Candidate
by Zacks Equity Research
BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid tumors.
Top 4 Value Stocks to Buy as Trade Tensions Still Cloud H2 Outlook
by Sumit Singh
STNE, CNC, CVS and PFE stand out as top value picks amid trade tensions and a murky H2 economic outlook.
Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study
by Zacks Equity Research
GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard care.
PFE or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PFE vs. LLY: Which Stock Is the Better Value Option?
Pfizer (PFE) Down 5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are Investors Undervaluing Pfizer (PFE) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY slides 20.7% in 3 months despite strong Q1 and raised outlook, as generic pressure and pipeline setbacks weigh on investor sentiment.